458 related articles for article (PubMed ID: 28894754)
1. Natural Modulators of Endosomal Toll-Like Receptor-Mediated Psoriatic Skin Inflammation.
Lai CY; Su YW; Lin KI; Hsu LC; Chuang TH
J Immunol Res; 2017; 2017():7807313. PubMed ID: 28894754
[TBL] [Abstract][Full Text] [Related]
2. Identification of Thiostrepton as a Novel Inhibitor for Psoriasis-like Inflammation Induced by TLR7-9.
Lai CY; Yeh DW; Lu CH; Liu YL; Huang LR; Kao CY; Chen HY; Huang CY; Chang CH; Luo Y; Xiang R; Chuang TH
J Immunol; 2015 Oct; 195(8):3912-21. PubMed ID: 26371257
[TBL] [Abstract][Full Text] [Related]
3. IMO-8400, a toll-like receptor 7, 8, and 9 antagonist, demonstrates clinical activity in a phase 2a, randomized, placebo-controlled trial in patients with moderate-to-severe plaque psoriasis.
Balak DM; van Doorn MB; Arbeit RD; Rijneveld R; Klaassen E; Sullivan T; Brevard J; Thio HB; Prens EP; Burggraaf J; Rissmann R
Clin Immunol; 2017 Jan; 174():63-72. PubMed ID: 27876460
[TBL] [Abstract][Full Text] [Related]
4. Suppression of molecular inflammatory pathways by Toll-like receptor 7, 8, and 9 antagonists in a model of IL-23-induced skin inflammation.
Suárez-Fariñas M; Arbeit R; Jiang W; Ortenzio FS; Sullivan T; Krueger JG
PLoS One; 2013; 8(12):e84634. PubMed ID: 24386404
[TBL] [Abstract][Full Text] [Related]
5. Oligodeoxynucleotide inhibition of Toll-like receptors 3, 7, 8, and 9 suppresses cytokine production in a human rheumatoid arthritis model.
Sacre S; Lo A; Gregory B; Stephens M; Chamberlain G; Stott P; Brennan F
Eur J Immunol; 2016 Mar; 46(3):772-81. PubMed ID: 26593270
[TBL] [Abstract][Full Text] [Related]
6. Azithromycin impairs TLR7 signaling in dendritic cells and improves the severity of imiquimod-induced psoriasis-like skin inflammation in mice.
Huang SW; Chen YJ; Wang ST; Ho LW; Kao JK; Narita M; Takahashi M; Wu CY; Cheng HY; Shieh JJ
J Dermatol Sci; 2016 Oct; 84(1):59-70. PubMed ID: 27449383
[TBL] [Abstract][Full Text] [Related]
7. Involvement of M1 Macrophage Polarization in Endosomal Toll-Like Receptors Activated Psoriatic Inflammation.
Lu CH; Lai CY; Yeh DW; Liu YL; Su YW; Hsu LC; Chang CH; Catherine Jin SL; Chuang TH
Mediators Inflamm; 2018; 2018():3523642. PubMed ID: 30647534
[TBL] [Abstract][Full Text] [Related]
8. Mechanism of endosomal TLR inhibition by antimalarial drugs and imidazoquinolines.
Kuznik A; Bencina M; Svajger U; Jeras M; Rozman B; Jerala R
J Immunol; 2011 Apr; 186(8):4794-804. PubMed ID: 21398612
[TBL] [Abstract][Full Text] [Related]
9. A Toll-like receptor 7, 8, and 9 antagonist inhibits Th1 and Th17 responses and inflammasome activation in a model of IL-23-induced psoriasis.
Jiang W; Zhu FG; Bhagat L; Yu D; Tang JX; Kandimalla ER; La Monica N; Agrawal S
J Invest Dermatol; 2013 Jul; 133(7):1777-84. PubMed ID: 23370539
[TBL] [Abstract][Full Text] [Related]
10. TLRs to cytokines: mechanistic insights from the imiquimod mouse model of psoriasis.
Flutter B; Nestle FO
Eur J Immunol; 2013 Dec; 43(12):3138-46. PubMed ID: 24254490
[TBL] [Abstract][Full Text] [Related]
11. Paeonol ameliorates imiquimod-induced psoriasis-like skin lesions in BALB/c mice by inhibiting the maturation and activation of dendritic cells.
Meng Y; Wang M; Xie X; Di T; Zhao J; Lin Y; Xu X; Li N; Zhai Y; Wang Y; Li P
Int J Mol Med; 2017 May; 39(5):1101-1110. PubMed ID: 28339016
[TBL] [Abstract][Full Text] [Related]
12. Psoriasis triggered by toll-like receptor 7 agonist imiquimod in the presence of dermal plasmacytoid dendritic cell precursors.
Gilliet M; Conrad C; Geiges M; Cozzio A; Thürlimann W; Burg G; Nestle FO; Dummer R
Arch Dermatol; 2004 Dec; 140(12):1490-5. PubMed ID: 15611427
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic targeting of Toll-like receptors: a review of Toll-like receptors and their signaling pathways in psoriasis.
Rahmani F; Rezaei N
Expert Rev Clin Immunol; 2016 Dec; 12(12):1289-1298. PubMed ID: 27359083
[TBL] [Abstract][Full Text] [Related]
14. Toll-like receptors 7, 8, and 9: linking innate immunity to autoimmunity.
Krieg AM; Vollmer J
Immunol Rev; 2007 Dec; 220():251-69. PubMed ID: 17979852
[TBL] [Abstract][Full Text] [Related]
15. Multiple Immunosuppressive Effects of CpG-c41 on Intracellular TLR-Mediated Inflammation.
Liu W; Yang X; Wang N; Fan S; Zhu Y; Zheng X; Li Y
Mediators Inflamm; 2017; 2017():6541729. PubMed ID: 28539706
[TBL] [Abstract][Full Text] [Related]
16. Rutaecarpine inhibited imiquimod-induced psoriasis-like dermatitis via inhibiting the NF-κB and TLR7 pathways in mice.
Li Y; Zhang G; Chen M; Tong M; Zhao M; Tang F; Xiao R; Wen H
Biomed Pharmacother; 2019 Jan; 109():1876-1883. PubMed ID: 30551443
[TBL] [Abstract][Full Text] [Related]
17. A Novel Small-Molecule Inhibitor of Endosomal TLRs Reduces Inflammation and Alleviates Autoimmune Disease Symptoms in Murine Models.
Patra MC; Achek A; Kim GY; Panneerselvam S; Shin HJ; Baek WY; Lee WH; Sung J; Jeong U; Cho EY; Kim W; Kim E; Suh CH; Choi S
Cells; 2020 Jul; 9(7):. PubMed ID: 32660060
[TBL] [Abstract][Full Text] [Related]
18. Design, synthesis and biological evaluation of novel antagonist compounds of Toll-like receptors 7, 8 and 9.
Kandimalla ER; Bhagat L; Wang D; Yu D; Sullivan T; La Monica N; Agrawal S
Nucleic Acids Res; 2013 Apr; 41(6):3947-61. PubMed ID: 23396449
[TBL] [Abstract][Full Text] [Related]
19. The Role of Toll-Like Receptors in Skin Host Defense, Psoriasis, and Atopic Dermatitis.
Sun L; Liu W; Zhang LJ
J Immunol Res; 2019; 2019():1824624. PubMed ID: 31815151
[TBL] [Abstract][Full Text] [Related]
20. The dysfunctional innate immune response triggered by Toll-like receptor activation is restored by TLR7/TLR8 and TLR9 ligands in cutaneous lichen planus.
Domingues R; de Carvalho GC; da Silva Oliveira LM; Futata Taniguchi E; Zimbres JM; Aoki V; da Silva Duarte AJ; Sato MN
Br J Dermatol; 2015 Jan; 172(1):48-55. PubMed ID: 24976336
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
